Optinose to Report Third Quarter 2018 Financial Results and Corporate Updates on November 13, 2018

Loading...
Loading...

Conference Call and Webcast Scheduled for Tuesday, November 13 at 8:00 a.m. Eastern Time

YARDLEY, Pa., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Optinose OPTN, a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will release financial results for the third quarter 2018, before market open on Tuesday, November 13, 2018.

Members of the Company's leadership team will host a conference call to discuss financial results and corporate updates, including its launch of XHANCE®. The call is scheduled to start at 8:00 a.m. Eastern Time on Tuesday, November 13, 2018.

To participate on the conference call, please dial (866) 916-4761 from the U.S. or +1 (409) 216-6496 from outside the U.S. In addition, following the completion of the call, a telephone replay will be accessible until November 20, 2018 by dialing (855) 859-2056 from the U.S. or +1 (404) 537-3406 from outside the U.S. and entering conference ID #6156615. A simultaneous webcast of the call and presentation can be accessed by visiting the Investors section of Optinose's website at www.optinose.com. In addition, a replay of the webcast will be available on the Company website for 60 days following the event.

About Optinose
Optinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. Optinose has offices in the U.S., the U.K. and Norway. To learn more, please visit www.optinose.com or follow us on Twitter and LinkedIn.

Optinose Investor Contact
Jonathan Neely
Jonathan.neely@optinose.com
267.521.0531

Loading...
Loading...
Market News and Data brought to you by Benzinga APIs
Posted In: NewsPress ReleasesGeneral
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...